阿尔法(金融)
α-葡萄糖苷酶
类黄酮
生物信息学
α-淀粉酶
抑制性突触后电位
化学
生物化学
药理学
传统医学
医学
酶
淀粉酶
内科学
抗氧化剂
护理部
基因
患者满意度
结构效度
作者
Bùi Thanh Tùng,Lê Thị Hương,Trinh Thi Duong,Nguyen Thi Huyen,Nguyễn Thị Thuỷ
出处
期刊:VNU Journal of Science: Medical and Pharmaceutical Sciences
[Vietnam National University Journal of Science]
日期:2024-03-22
卷期号:40 (1)
被引量:1
标识
DOI:10.25073/2588-1132/vnumps.4581
摘要
Diabetes mellitus (diabetes) is a chronic disease associated with metabolic disorders and hyperglycemia. α-glucosidase and α-amylase, which play an important role in the hydrolysis of starch and carbohydrates, are enzymes. They are related to the increase and decrease in blood glucose levels. Flavonoids are a common group of natural compounds that have been shown to have many beneficial health effects. This study used molecular docking methods and drug-like criteria, predicting pharmacokinetics-toxicity (ADMET) to screen and evaluate potential flavonoid compounds in the treatment of type 2 diabetes. After screening the compounds, we obtained 46 compounds with lower binding energies than the positive controls, which are acarbose. Using Lipinski's rule of five, we evaluated the drug-likeness of the compounds and identified 12 compounds that met the criteria. Then, continuing to analyze according to pharmacokinetic and toxicological parameters (ADMET), we obtained 3 compounds including Galangin, Maackiain, and Corylin, that have the potential to be developed into drugs when showing the ability to simultaneously inhibit both enzymes α-glucosidase and α-amylase have positive properties: binding energy is lower than the control, creates many interactions with target proteins in the active site, has drug-like properties, relatively good pharmacokinetic properties and low toxicity. Therefore, further in vitro and in vivo studies are needed to develop these potential compounds into drugs for the treatment of type 2 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI